Clinical characteristics of patients with lung cancer and idiopathic pulmonary fibrosis in China

被引:12
作者
Xu, Yan
Zhong, Wei
Zhang, Li
Zhao, Jing
Li, Longyun
Wang, Mengzhao [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Dis, Beijing 100730, Peoples R China
关键词
IPF; lung cancer; lung cancer treatment; tumor markers; TOXICITY; CELLS;
D O I
10.1111/j.1759-7714.2012.00108.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To identify distinguishing characteristics between patients with lung cancer and idiopathic pulmonary fibrosis (IPF-CA) and patients with IPF alone in China. Methods: The medical records of 24 IPF-CA patients and 80 IPF patients admitted to Peking Union Medical College Hospital (PUMCH) from 1999 to 2009 were reviewed. Results: The incidence of lung cancer in IPF patients in our study was 23.1% (24/104), and the percentage of patients who smoked in the IPF-CA group was higher than the IPF group (87.5% and 55.0%, respectively, P = 0.004). Three symptoms, including productive cough, hemoptysis, and chest pain, were more common in IPF-CA patients than IPF alone patients. There was no significant difference in the percentage of patients with other abnormal serum tumor markers, except that the percentage of patients with abnormal neuron specific enolase was significantly higher in the IPF-CA group than in the IPF group (28.6% vs. 7.4%, P = 0.041). The most common histology type was adenocarcinoma (33.3%). The median overall survival for IPF-CA patients and IPF patients was 7.0 months (95% confidential interval (CI), 2.5111.49) and 14.0 months (95% CI, 1.2626.74), respectively, with no significant difference (P = 0.327). Conclusion: Due to a high proportion of IPF cases complicated with lung cancer, physicians should closely observe lung cancer incidence during the IPF follow-up period. Individualized treatment for lung cancer patients with IPF is emphasized. Hence, it is important to ensure the safety of cancer treatments.
引用
收藏
页码:156 / 161
页数:6
相关论文
共 23 条
[1]   Does interstitial lung disease predispose to lung cancer? [J].
Daniels, CE ;
Jett, JR .
CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (05) :431-437
[2]   The New Lung Cancer Staging System [J].
Detterbeck, Frank C. ;
Boffa, Daniel J. ;
Tanoue, Lynn T. .
CHEST, 2009, 136 (01) :260-271
[3]  
Fujita J, 1998, Respirology, V3, P211, DOI 10.1111/j.1440-1843.1998.tb00124.x
[4]   Evaluation of patients with pulmonary nodules: When is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition) [J].
Gould, Michael K. ;
Fletcher, James ;
Iannettoni, Mark D. ;
Lynch, William R. ;
Midthun, David E. ;
Naidich, David P. ;
Ost, David E. .
CHEST, 2007, 132 (03) :108S-130S
[5]   Prognostic value of serum carcinoembryonic antigen levels in patients who undergo lung transplantation [J].
Hadjiliadis, D ;
Tapson, VF ;
Davis, RD ;
Palmer, SM .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2001, 20 (12) :1305-1309
[6]   Non-small cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis [J].
Kong, FM ;
Ten Haken, R ;
Eisbruch, A ;
Lawrence, TS .
SEMINARS IN ONCOLOGY, 2005, 32 (02) :S42-S54
[7]   The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK [J].
Le Jeune, Ivan ;
Gribbin, Jonathan ;
West, Joe ;
Smith, Chris ;
Cullinan, Paul ;
Hubbard, Richard .
RESPIRATORY MEDICINE, 2007, 101 (12) :2534-2540
[8]   Lung cancer in patients with idiopathic pulmonary fibrosis: CT findings [J].
Lee, HJ ;
Im, JG ;
Ahn, JM ;
Yeon, KM .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1996, 20 (06) :979-982
[9]   Pulmonary toxicity associated with erlotinib [J].
Liu, Vincent ;
White, Dorothy A. ;
Zakowski, Maureen F. ;
Travis, William ;
Kris, Mark G. ;
Ginsberg, Michelle S. ;
Miller, Vincent A. ;
Azzoli, Christopher G. .
CHEST, 2007, 132 (03) :1042-1044
[10]  
Ma Y, 2001, Curr Opin Pulm Med, V7, P278, DOI 10.1097/00063198-200109000-00005